Northern Trust
RNAC icon

Northern Trust’s Cartesian Therapeutics RNAC Stock Holding History

Northern Trust’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$566K Buy
91,992
+4,979
+6% +$35.5K ﹤0.01% 3568
2025
Q4 		$627K Sell
87,013
-4,276
-5% -$34.6K ﹤0.01% 3574
2025
Q3 		$933K Buy
91,289
+8,345
+10% +$93.8K ﹤0.01% 3435
2025
Q2 		$862K Sell
82,944
-9,393
-10% -$100K ﹤0.01% 3457
2025
Q1 		$1.22M Sell
92,337
-2,693
-3% -$48.1K ﹤0.01% 3195
2024
Q4 		$1.7M Buy
95,030
+31,915
+51% +$646K ﹤0.01% 3116
2024
Q3 		$1.02M Buy
63,115
+32,191
+104% +$503K ﹤0.01% 3349
2024
Q2 		$835K Sell
30,924
-258
-0.8% -$6.16K ﹤0.01% 3320
2024
Q1 		$608K Sell
31,182
-341
-1% -$7.23K ﹤0.01% 3497
2023
Q4 		$652K Sell
31,523
-55
-0.2% -$1.64K ﹤0.01% 3455
2023
Q3 		$1M Buy
31,578
+471
+2% +$15.7K ﹤0.01% 3298
2023
Q2 		$1.05M Buy
31,107
+24,159
+348% +$865K ﹤0.01% 3346
2023
Q1 		$290K Sell
6,948
-169
-2% -$7.94K ﹤0.01% 3681
2022
Q4 		$241K Hold
7,117
– – ﹤0.01% 3782
2022
Q3 		$350K Buy
7,117
+491
+7% +$27K ﹤0.01% 3628
2022
Q2 		$260K Sell
6,626
-19,394
-75% -$575K ﹤0.01% 3784
2022
Q1 		$960K Sell
26,020
-1,480
-5% -$92.6K ﹤0.01% 3431
2021
Q4 		$2.69M Sell
27,500
-671
-2% -$72.2K ﹤0.01% 3068
2021
Q3 		$3.52M Buy
28,171
+7,907
+39% +$955K ﹤0.01% 2957
2021
Q2 		$2.54M Sell
20,264
-4,185
-17% -$498K ﹤0.01% 3247
2021
Q1 		$3.32M Sell
24,449
-2,181
-8% -$271K ﹤0.01% 2993
2020
Q4 		$2.42M Sell
26,630
-276
-1% -$23.9K ﹤0.01% 3099
2020
Q3 		$2M Buy
26,906
+21,711
+418% +$1.66M ﹤0.01% 3059
2020
Q2 		$443K Buy
5,195
+2,435
+88% +$221K ﹤0.01% 3586
2020
Q1 		$199K Sell
2,760
-56
-2% -$5.41K ﹤0.01% 3686
2019
Q4 		$201K Buy
2,816
+198
+8% +$9.55K ﹤0.01% 3797
2019
Q3 		$137K Sell
2,618
-10,019
-79% -$532K ﹤0.01% 3855
2019
Q2 		$678K Sell
12,637
-1,368
-10% -$93.2K ﹤0.01% 3474
2019
Q1 		$995K Buy
14,005
+6,851
+96% +$434K ﹤0.01% 3358
2018
Q4 		$572K Buy
7,154
+7
+0.1% +$1.6K ﹤0.01% 3522
2018
Q3 		$3.33M Buy
7,147
+1,923
+37% +$773K ﹤0.01% 2931
2018
Q2 		$2.08M Buy
5,224
+554
+12% +$197K ﹤0.01% 3192
2018
Q1 		$1.43M Buy
4,670
+54
+1% +$15.4K ﹤0.01% 3268
2017
Q4 		$1.36M Sell
4,616
-62
-1% -$27.1K ﹤0.01% 3306
2017
Q3 		$2.56M Buy
4,678
+645
+16% +$343K ﹤0.01% 3031
2017
Q2 		$2.4M Buy
4,033
+2,717
+206% +$1.2M ﹤0.01% 3068
2017
Q1 		$566K Buy
1,316
+84
+7% +$35.3K ﹤0.01% 3498
2016
Q4 		$634K Buy
+1,232
New +$720K ﹤0.01% 3471

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust's RNAC Position: Q1 2026 in Review

Northern Trust increased its Cartesian Therapeutics (RNAC) stake by 5.7% in Q1 2026, buying an estimated $35.5K and bringing the position to 91,992 shares worth $566K. The position accounts for ﹤0.01% of the portfolio, ranked #3568.

Northern Trust first reported a position in RNAC in Q4 2016 and has held it in 38 quarters since. The position peaked at $3.52M in Q3 2021. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • Northern Trust held 91,992 shares of Cartesian Therapeutics worth $566K as of Q1 2026.
  • Northern Trust bought 4,979 Cartesian Therapeutics shares in Q1 2026, an estimated $35.5K.
  • Cartesian Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #3568 holding.
  • Northern Trust first reported a position in Cartesian Therapeutics in Q4 2016 and has held it in 38 quarters since.
  • Northern Trust's Cartesian Therapeutics position peaked at $3.52M in Q3 2021.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.